Larazotide acetate
AT-1001 · INN-202 · C34H55N9O10 · monoisotopic 749.4072 Da. The index holds 0 assay reports on this compound across 0 batches from 0 suppliers.
Analytical fingerprint
Hand-authored chemistry. These properties describe the substance and do not change when a record is added.
Larazotide is an octapeptide intended for oral use, and the index sees it submitted as capsule contents about as often as as lyophilised powder. Capsule submissions are recorded with an excipient note: microcrystalline cellulose does not chromatograph but it does affect the gravimetric mass balance, and larazotide is the compound where the index's water/counter-ion/residual reconciliation most often has to be reported as not applicable.
- Compound class
- Tissue-repair and immunomodulatory peptides
- Molecular formula
- C34H55N9O10
- Monoisotopic mass
- 749.4072Da
- Average mass
- 749.86Da
- Residues
- 8
- Nominal retention (RG-2, 30 min)
- 7.44min
- Retention window
- 0.25min
- Counter-ion as usually shipped
- acetate
- Typical label claims
- 5 mg · 10 mg
- Analytical difficulty (index scale)
- 0.85 — straightforward
- Purity is a defined quantity
- YES
What the index has observed
Arithmetic over the 0 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.
The index holds no records for Larazotide acetate carrying a purity figure. That is a gap in the index, not a finding about the compound.
Characteristic impurities and degradants
The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.
| Named species | ΔRT (min, RG-2) | Δ mass (Da) | Seen in | Median % area | Max % area |
|---|---|---|---|---|---|
| des-Gly truncate (−57 Da) | -0.26 | -57.021 | — | not observed | — |
| diketopiperazine (−18 Da) | +0.20 | -18.011 | — | not observed | — |
| [D-Pro]-diastereomer | -0.10 | mass-identical | — | not observed | — |
| acetyl adduct (+42 Da) | +0.36 | +42.011 | — | not observed | — |
Degradation pathways
- diketopiperazine formation
- C-terminal hydrolysis
Full impurity profile, with what each named species implies about the synthesis →
Clinical context
Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.
Larazotide's phase 3 coeliac disease trial (CeDLara) did not meet its endpoint; it was discontinued in 2022.
Quarterly coverage
Most recent records
No records yet. Submitting one is the only way this changes.